MARKET

RPTX

RPTX

Repare Therapeutics Inc.
NASDAQ
2.810
-0.160
-5.39%
After Hours: 2.780 -0.03 -1.07% 16:09 11/22 EST
OPEN
2.970
PREV CLOSE
2.970
HIGH
3.090
LOW
2.776
VOLUME
139.08K
TURNOVER
--
52 WEEK HIGH
8.49
52 WEEK LOW
2.710
MARKET CAP
119.46M
P/E (TTM)
-1.4078
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RPTX last week (1111-1115)?
Weekly Report · 6d ago
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher
Simply Wall St · 11/13 12:01
Repare Therapeutics collaborates with U.S. National Cancer Institute
Seeking Alpha · 11/12 14:36
Repare Therapeutics announces CRADA to advance camonsertib development
TipRanks · 11/12 12:40
REPARE THERAPEUTICS ANNOUNCES AGREEMENT WITH THE US NATIONAL CANCER INSTITUTE TO ADVANCE THE DEVELOPMENT OF CAMONSERTIB
Reuters · 11/12 12:05
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
TipRanks · 11/11 13:21
Weekly Report: what happened at RPTX last week (1104-1108)?
Weekly Report · 11/11 09:19
Repare Therapeutics: Promising Oncology Advances and Financial Stability Support Buy Rating
TipRanks · 11/11 05:15
More
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Webull offers Repare Therapeutics Inc stock information, including NASDAQ: RPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPTX stock methods without spending real money on the virtual paper trading platform.